Skip to main content
Premium Trial:

Request an Annual Quote

Set the Date

Daniel MacArthur gives us the lowdown from AGBT, the annual sequencing bonanza. While there's a lot of good data being presented, the overarching theme is the evolving battle between third-gen sequencing companies, he says at Genetic Future. Illumina said in a presentation early in the week that they'd be able to "routinely generate 95 Gb (that's 95 billion bases, the equivalent of 30 human genomes) of DNA sequence per run" by the end of the year. "Most people I spoke to seemed to feel that Illumina's claims were quite realistic -- and they'd better be, because competition is coming from relative newcomers to the field." Complete Genomics CEO Clifford Reid brought the drama, as well as some preliminary data, in his talk. "I think there was little doubt in the audience's mind that this is a serious new contender in the DNA sequencing field," MacArthur writes.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.